| Serum sialic acid changes in type 2 diabetic patients on metformin or rosiglitazone treatment. | |
| | |
MedLine Citation:
|
PMID: 21054460 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
WHAT IS KNOWN AND OBJECTIVE: Serum sialic acid is a recently investigated potential risk-marker for cardiovascular complications. There is a known association between sialic acid and cardiovascular complications in diabetes mellitus. We aimed to investigate the effect of antidiabetic drugs on the serum concentration of sialic acid. METHODS: We investigated the effect of metformin and rosiglitazone on the concentration of sialic acid in 120 type 2 diabetic patients, divided into a group (n = 60) receiving metformin and a group (n = 60) receiving rosiglitazone treatment. RESULTS: Serum sialic acid was significantly higher in patients on rosiglitazone (66·90 ± 8·80 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·01) and metformin (61·95 ± 10·49 mg/dL vs. 57·6 ± 8·46 mg/dL, P < 0·04) when compared with control subjects. In addition, rosiglitazone-treated patients showed a significant increase in cardiovascular risk factors, notably total cholesterol (246·45 ± 20·2 mg/dL vs. 170·6 ± 15·1 mg/dL, P = 0·01), triglyceride (178 ± 9·20 mg/dL vs. 149·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) concentration (8·17 ± 1·43% vs. 4·38 ± 0·96%, P < 0·02) compared with normal control subjects. The patients on metformin also showed significantly higher levels of serum glucose (133·7 ± 9·63 mg/dL vs. 88·35 ± 6·31 mg/dL, P < 0·04) and glycohemoglobin (HbA1-c) (8·23 ± 1·75% vs. 4·38 ± 0·96%, P < 0·02) when compared with control subjects. Comparison of the two groups of patients revealed a significantly higher serum sialic acid (66·90 ± 8·80 mg/dL vs. 61·95 ± 10·49 mg/dL, P < 0·05), total cholesterol (246·45 ± 20·2 mg/dL vs. 192 ± 14·23 mg/dL, P < 0·02) and triglyceride (178 ± 9·20 mg/dL vs. 158 ± 14·51mg/dL, P < 0·05) concentrations in the rosiglitazone-treated patients. WHAT IS NEW AND CONCLUSIONS: This study suggests significantly higher levels of serum sialic acid and other cardiovascular risk factors in rosiglitazone-treated patients than in metformin-treated patients. The lower sialic acid concentration may explain a better metformin antidiabetic effect than with rosiglitazone. |
| | |
Authors:
|
I U Rahman; S A Malik; M Bashir; R U Khan; M Idrees |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of clinical pharmacy and therapeutics Volume: 35 ISSN: 1365-2710 ISO Abbreviation: J Clin Pharm Ther Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-08 Completed Date: 2011-05-17 Revised Date: 2012-09-10 |
Medline Journal Info:
|
Nlm Unique ID: 8704308 Medline TA: J Clin Pharm Ther Country: England |
Other Details:
|
Languages: eng Pagination: 685-90 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Faculty of Biological Sciences, Quaid e Azam University, Islamabad, Pakistan. marwax07@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood Blood Glucose / drug effects Cardiovascular Diseases / etiology Cholesterol / blood Diabetes Mellitus, Type 2 / blood, drug therapy* Female Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / therapeutic use* Lipids / blood Male Metformin / therapeutic use* N-Acetylneuraminic Acid / blood* Risk Risk Factors Thiazolidinediones / therapeutic use* Triglycerides / blood |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Lipids; 0/Thiazolidinediones; 0/Triglycerides; 122320-73-4/rosiglitazone; 131-48-6/N-Acetylneuraminic Acid; 57-88-5/Cholesterol; 657-24-9/Metformin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Methylprednisolone reduces postoperative nausea in total knee and hip arthroplasty.
Next Document: Modification of propranolol's bioavailability by Eurycoma longifolia water-based extract.